ABSTRACT
Introduction
Pseudomonas aeruginosa, a ubiquitous Gram-negative soil organism, is widely distributed in nature. P. aeruginosa is noted for its metabolic versatility and its exceptional ability to colonize a wide variety of environments, and also for its intrinsic resistance to a wide variety of antimicrobial agents. Such characteristics result in a higher prevalence of this organism in hospital environments, where it is a clinically significant pathogen causing opportunistic infections and nosocomial outbreaks [1, 2] . P. aeruginosa typically infects injured, burned, immune deficient, or immunocompromised patients and causes a variety of infections. The bacterium has various virulence determinants, such as adhesins [3] , toxins [4] , capsules [5], and biofilms [6] , and is also frequently resistant to many commonly used antibiotics [7] . Though many strains of P. aeruginosa are susceptible to cephalosporins, carbenicillin, gentamicin, tobramycin, colistin, polymyxin, and fluoroquinolones, strains resistant to those antibiotics are increasing in medical care facilities and isolation of the multidrug-resistant strain have been reported [8] [9] [10] [11] [12] .
One of the challenges in managing P. aeruginosa infections is an inherent resistance mechanism, referred to as intrinsic resistance. Because of its virulence and the limited choices of effective antimicrobial agents, treatment of P. aeruginosa infection is often complicated. The present study aimed to study the antimicrobial susceptibility patterns of P. aeruginosa isolated from outpatients and inpatients, using the agar dilution method, and by defining mutations in gyrA, parC, mexZ, mexR and nfxB, which contribute to fluoroquinolon resistance, in these isolates.
Materials and Methods

Antibacterial Agents and Bacterial Strains
Ciprofloxacin, meropenem, and amikacin were purchased from Wako Pure Chemical Industries, Ltd., Japan, and pazufloxacin was purchased from Toyama Chemical Co., Ltd., Japan.
In this study, 373 clinical isolates of P. aeruginosa were collected during September 2010 to September 2011 at Toho University Ohashi Medical Center. Of these, 321 isolates of P. aeruginosa were obtained from inpatients with respiratory tract infections, urinary tract infections, surgical site infection, gastrointestinal tract infections, or bacteremia, whereas the remaining 52 isolates were obtained from outpatients with tympanitis, bacterial skin infections, respiratory tract infections, or urinary tract infections. All the P. aeruginosa strains isolated were maintained in Microbank TM (Pro-Lab, Toronto, Canada) and kept at -80˚C.
Determination of MIC
MICs were determined by the standard agar dilution assay, according to guidelines of the National Committee for Clinical Laboratory Standards (NCCLS), using Mueller-Hinton (MH) agar (Becton, Dickinson and Company, USA). Strains preserved on Microbank TM were inoculated into 2 mL of MH broth and incubated at 37˚C for 18 -20 h. After dilution with MH broth, 2 μL of the bacterial suspension containing 10 4 CFU was spotted onto drug-containing agar plates. The plates were incubated at 37˚C for 24 h. The MIC was defined as the lowest drug concentration that prevented visible growth of bacteria.
Statistical Analysis
Mann-Whitney's U-test was used to evaluate the relationship between the distribution of MIC of CPFX, MEPM, PZFX and AMK in the strains of P. aeruginosa isolated from outpatients and inpatients.
PCR Amplification and DNA Sequence Determination and Analysis
The strains were incubated in MH broth at 37˚C overnight, and 1 mL of the culture was centrifuged (15,000 rpm, 10 min, at 4˚C 
Impact of Efflux Pump Inhibitor (EPI) on the MICs of Ciprofloxacin
Strains of P. aeruginosa of which the ciprofloxacin MIC exceeded 3.91 μg/mL were inoculated on agar plates containing various concentrations of ciprofloxacin, with or without 20 μg/mL of the efflux pump inhibitor, phenylalanine arginyl-β-naphtylamide (Sigma-Aldrich, MO, USA). MICs of ciprofloxacin in the presence of EPI were 
Results and Discussion
Antibiogram Pattern of Pseudomonas aeruginosa
The results of MH agar-based antibiogram pattern study of the strains of P. aeruginosa isolated from inpatients (n = 321) and outpatients (n = 52) is shown in Figure 1 . The MIC range of CPFX in the strains isolated from outpatients, except for 1 strain, was between <0.06 and 1.95 μg/mL, but that of strains isolated from inpatients was between <0.06 and >62.5 μg/mL (Figure 1(a) ). Thus, strains from outpatients were sensitive to CPFX, except for 1 strain that was isolated from an outpatient who had received ofloxacin treatment for chronic otitis media. The percentage of CPFX-non-susceptible strains (≥3.91 μg/mL) among inpatients was 22.4%, but that among outpatients was 1.9%. The MIC range of the strains from outpatients for PZFX was between 0.06 and 7.81 μg/mL, except for 1 strain, and that from inpatients was between <0.06 and 62.5 μg/mL (Figure 1(c) ).
The MIC ranges of the strains from outpatients and inpatients for MEPM were between <0.49 and 7.81 μg/mL, and between <0.49 and >125 μg/mL, respectively. The percentage of MEPM-non-susceptible strains (≥15.6 μg/mL) among inpatients was 30.5%, but there were no MEPM-non-susceptible strains among outpatients (Figure 1(b) ).
The MIC ranges of the strains from outpatients for AMK was between <0.49 and 15.62 μg/mL, and that from inpatients was between <0.49 and 62.5 μg/mL. The percentage of AMK-non-susceptible strains (≥31.25 μg/ mL) from inpatients was 5.6%, but no AMK-non-susceptible strains were found among outpatients ( Figure  1(d) ).
Our results indicated that most of the strains isolated from outpatients were susceptible to CPFX and PZFX, but 22.4% of the strains isolated from inpatients were resistant to CPFX; strains isolated from outpatient were susceptible to MEPM, but 30.5% of the strains isolated from inpatients were resistant to MEPM (Figure 1(b) ). Similarly, strains isolated from outpatients were susceptible to AMK, but 5.6 % of the strains isolated from inpatients were resistant to this antimicrobial agent ( Figure  1(d) ).
Statistical OJMM were resistant to CPFX, while 22% were resistant to MEPM [13] ; furthermore, 42.9% of 207 isolates from 1 medical facility were resistant to CPFX, while 12.6% were resistant to MEPM [14] . In another study, among 188 strains isolated from 139 cases in a number of medical facilities, 24% were resistant to CPFX, whereas 18% were resistant to MEPM [15] . The differences in resistance rates among the present study and the surveys mentioned above could reflect differences in clinical usage of antimicrobial agents and periods of administration, etc.
Relationship between MIC and Mutations in gyrA and parC
As mentioned above, 22.4% of the P. aeruginosa strains isolated from inpatients were not susceptible to CPFX; we then set out to identify mutations in gyrA and parC that may underlie this CPFX-resistance. Strains of P. aeruginosa repeatedly isolated from the same patient, or strains with MICs exceeding 3.91 μg/mL for CPFX or PZFX were selected. Mutations in gyrA and parC of 131 strains were analyzed by PCR and DNA sequencing. As shown in Figure 2 (a), we found no mutations in the PCR-amplified gyrA and parC fragments from 52 of 60 strains with MICs less than 3.91 μg/mL for CPFX. The remaining 8 strains had a mutation only in gyrA; these mutations resulted in a Thr83Ile substitution in GyrA in 4 strains, an Asp87Gly substitution in 3 strains, and an Asp87Asn substitution in 1 strain. Nine of 46 strains with a MIC range from ≥3.91 μg/mL to <15.6 μg/mL for CPFX had no mutation in gyrA and parC, whereas 35 of these 46 strains had a mutation in only gyrA. Two strains had mutations in both gyrA and parC. Two of 25 strains with MICs for CPFX of ≥15.6 μg/mL had no mutation, 15 of these 25 strains had a mutation only in gyrA, and 8 strains had mutations in both gyrA and parC.
A similar analysis was performed in strains with MICs for PZFX of less than 3.91 μg/mL, ≥3.91 μg/mL to <15.6 μg/mL, and ≥15.6 μg/mL (Figure 2(b) ). No strains with MICs of less than 3.91 μg/mL for PZFX had mutations in gyrA and parC. In the 27 strains with a MIC range of ≥3.91 μg/mL to <15.6 μg/mL for PZFX, 7 had no mutations in gyrA or parC, 16 strains had a mutation only in gyrA, and 4 strains had mutations in both gyrA and parC. Two of 52 strains with MICs for PZFX of 15.6 μg/mL or more had no mutations, 42 of the 52 strains had a mutation only in gyrA, and 8 strains had mutations in both gyrA and parC.
We found no CPFX-or PZFX-resistant strain with a mutation only in parC. In Gram-positive cocci, mutations in parC are seen commonly in fluoroquinolone-resistant strains, and it is well-known that these mutations precede mutations in gyrA [16, 17] . The inverse, i.e., that mutations in gyrA precede mutations in parC, is typically seen in Gram-negative bacteria. In this study, CPFX-resistant strains had mutations in gyrA, while some strains had mutations in both gyrA and parC, similar to the finding in fluoroquinolone-resistant Gram-negative bacteria. Moreover, the strains with mutations in both gyrA and parC had higher MICs for CPFX [18, 19] .
Impact of Efflux Pump Inhibition on MICs of Ciprofloxacin
Interestingly, we found strains with high MICs for fluoroquinolones without mutations in either gyrA or parC. These higher CPFX-resistant strains were assumed to have other fluoroquinolone-resistance mechanisms, such as an overproduction of efflux pumps. To investigate this possibility, we used phenylalanine arginyl β-naphtylamide (PAβN), which inhibits efflux pumps in P. aeruginosa. [20] . resistant strains showed an 8-fold decrease in CPFX-MIC in the presence of PAN. Strains 109 and 225 had an alteration only in GyrA (Thr83Ile), and the MICs for CPFX of these strains (31.25 µg/mL) were higher than those of strains with the same GyrA alteration. However, MICs of these strains were decreased to 3.91 µg/mL in the presence of PAN. Similar MIC decreases were observed in strains with no alterations in GyrA and ParC. Therefore, overexpression of efflux pumps appears to contribute to the higher CPFX-resistance in these 12 strains.
Mutations in gyrA, parC, mexZ, mexR and nfxB in Clinical Isolates from Inpatients
As mentioned above, not only mutations in DNA topoisomerase II, but also those in genes regulating efflux pumps could contribute to CPFX-resistance in P. aeruginosa. We sequenced gyrA, parC, mexZ, mexR, and nfxB in 120 P. aeruginosa strains isolated from inpatients. The sequences were compared with the corresponding sequences of P. aeruginosa PAO1 (Pseudomonas Genome Database, http://www.pseudomonas.com/). The isolates were grouped into 12 groups on the basis of the amino acid substitutions found in GyrA, ParC, MexZ, MexR, and NfxB as shown in Table 3 . No mutation were found in these genes in 52 strains (Group I), but MICs of CPFX in 11 of these strains were ≥3.91 µg/mL. Strains with mutations in mexZ, or mexZ and mexR, were sensitive to 3.91 µg/mL CPFX. The mutation most frequently found in mexZ was a single base substitution that resulted in a missense mutation (C490T; 15 of 27 strains). Other mutations identified in mexZ were single base deletions leading to frame-shifts after Glu114 and Glu146, and 5-bp deletions leading to frame-shifts following Ala21 or Gly148. However, when comparing the MIC ranges of Groups V and VII, the contribution of these mexZ mutations to CPFX-resistance was not significant. Amino acid substitutions in MexR were found in 31 of 120 strains; the Val126Glu substitution was found in 30 of 31 strains, and 1 strain carried substitutions Val126-Glu and Ser92Asn. As for mexZ mutations, the mexR mutations found in this study did not have a significant effect on CPFX-resistance. Two strains had an 11-bp deletion in nfxB leading to a frame-shift following Val35; these strains also had other alterations affecting GyrA, ParC, MexZ, and MexR. Amino acid substitutions in quinolone resistance-determining region (QRDR) of GyrA (Thr83Ile or Asp87Asn) were found in 60 of 120 isolates; moreover, the Thr83Ile substitution was the mutation most frequently reported previously in CPFX-resistant clinical isolates of P. aeruginosa [21, 22] . Fifteen strains in Group V with an amino acid substitution in QRDR of GyrA (Thr83Ile) were resistant to 3.91 μg/mL CPFX, but 2 of 6 strains in Group IV with another amino acid substitution in QRDR of GyrA (Asp87Asn) were resistant to 3.91 μg/mL CPFX.
The only amino acid substitution found in QRDR of the ParC subunit of topoisomerase IV, another target of CPFX, was Ser87Leu; this alteration was always found along with a GyrA alteration (Groups IX-XII). These results suggested that CPFX-resistance in P. aeruginosa is mainly mediated through alterations in GyrA, and that alterations in ParC are secondary, as reported previously [23] . Alterations in ParC, MexZ, MexR, or NfxB in addition to mutation in GyrA (Thr83Ile) increased the MICs for CPFX, although the number of strains with multiple alterations was limited.
Our results revealed that multiple alterations in GyrA, ParC, MexZ, MexR, and NfxB were associated with a higher-level resistance to CPFX than that caused by a single alteration in GyrA. Although 2 strains in Group I (Table 3) , in which we could not identify mutatition in QRDRs of gyrA, parC, or the efflux pump regulator genes mexZ, mexR, and nfxB, were resistant to >7.81 µg/mL CPFX, the MICs of CPFX in strains 286 and 297 decreased from 15.6 µg/mL to 1.95 or 0.98 µg/mL in the presence of PAN, respectively ( Table 2) . A similar effect of PAN on the MICs of Group III strains, which had a GyrA (Thr83Ile) alteration, but no alterations in efflux pump regulators, was observed in 9 of 14 strains. These results suggested that over expression of other active efflux systems or decreased permeability could contribute to CPFX-resistance in these strains [24] .
